Generate Biomedicines, Inc. (GENB) Market Cap & Valuation Ratios
Generate Biomedicines, Inc. (GENB) has a market cap of $1.6B and a price-to-sales ratio of 252.3, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · read by EquiReason
GENBGenerate Biomedicines, Inc.Follow GENB — free
—
Price chart with a free account
- Market cap
- 1.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Peers
drug manufacturers - general · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| GENB | 1.6 | — | — | — | — | — | — | — |
| ZLAB | 2.7 | — | 5.2 | — | -5.2% | +5% | -59% | -112% |
| HCM | 2.5 | 143.6 | 2.2 | — | 0.4% | -9% | -6% | -3% |
| BHC | 2.4 | — | 2.0 | 10.4 | — | +10% | 8% | 4% |
| NAMS | 2.4 | — | 241.9 | — | -6.1% | -89% | — | -116% |
| BRVE | 1.9 | — | — | — | — | — | — | — |
| QURE | 1.6 | — | 42.6 | — | -10.4% | +30% | — | — |
| CMPS | 1.5 | — | — | — | — | — | — | — |
| GPCR | 1.5 | — | — | — | -14.9% | — | — | -30% |
| MLTX | 1.0 | — | — | — | — | — | — | -315% |
| SLN | 0.9 | — | — | — | -4.5% | -98% | — | — |
| Median of these 10 | 143.6 | 5.2 | 10.4 | -5.6% | -2% | -6% | -71% |
.
Growth vs. price
each dot a company · hover or tap for valuesGenerate Biomedicines, Inc. — questions
- What is Generate Biomedicines, Inc.'s market cap?
- $1.6B.
- What is Generate Biomedicines, Inc.'s price-to-sales ratio?
- 252.3.
Every figure on this page comes from Generate Biomedicines, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.